(Q82758717)
English
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
scientific article published on 02 February 2010
Statements
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens (English)
Jean-Yves Douillard
Jaafar Bennouna
Istvan Lang
Manuel Valladares-Ayerbes
Katalin Boer
Antoine Adenis
Pilar Escudero
Tae-You Kim
Gillian M Pover
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference